Isabel Ramis
R&D Centre
Barcelona, CT, Spain
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Discovery of LAS194046: A Potent and Selective pan-Janus Kinase (JAK) Inhibitor with a Suitable Profile for Inhaled Administration.
Journal: Journal of medicinal chemistry
Published: January 16, 2026
The pan-JAK inhibitor LAS194046 reduces neutrophil activation from severe asthma and COPD patients in vitro.
Journal: Scientific reports
Published: September 15, 2021
Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases.
Journal: Journal of medicinal chemistry
Published: October 15, 2019
Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats.
Journal: The Journal of pharmacology and experimental therapeutics
Published: January 03, 2019
PI3K, p38 and JAK/STAT signalling in bronchial tissue from patients with asthma following allergen challenge.
Journal: Biomarker research
Published: November 01, 2017
Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS.
Journal: Pulmonary pharmacology & therapeutics
Published: July 25, 2016
Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients.
Journal: Respiratory research
Published: May 05, 2016
A novel inhaled Syk inhibitor blocks mast cell degranulation and early asthmatic response.
Journal: Pharmacological research
Published: March 23, 2015
Highly potent aminopyridines as Syk kinase inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: May 16, 2012
Pyrazine-based Syk kinase inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: January 25, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026